Chris Shibutani
Stock Analyst at Goldman Sachs
(3.43)
# 925
Out of 4,748 analysts
100
Total ratings
56%
Success rate
3.12%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Initiates: Buy | $135 | $91.38 | +47.74% | 1 | Dec 20, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $125.37 | +9.28% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $14.42 | +128.93% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $374.50 | -19.36% | 4 | Nov 1, 2024 | |
| ALKS Alkermes | Maintains: Buy | $32 → $30 | $31.34 | -4.28% | 6 | Oct 25, 2024 | |
| ERAS Erasca | Maintains: Buy | $3 → $3.5 | $1.86 | +88.68% | 6 | Oct 25, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $31.80 | +60.38% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $151.51 | +2.30% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $3.59 | +11.58% | 8 | Jul 12, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $9 → $8 | $3.66 | +118.88% | 5 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $16.00 | +25.00% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $808.93 | -10.62% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $25.19 | +3.22% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $152.79 | +0.14% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $176.64 | -2.06% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.84 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $1.25 | $0.80 | +56.05% | 3 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $59.64 | +15.69% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $18.87 | -31.11% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $41.09 | -44.02% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.97 | +2,438.07% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $39.73 | +30.88% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $26.94 | +122.76% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $13.11 | +37.30% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $3.17 | +436.28% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.15 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.44 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.07 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.45 | - | 3 | May 2, 2017 |
Vaxcyte
Dec 20, 2024
Initiates: Buy
Price Target: $135
Current: $91.38
Upside: +47.74%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $125.37
Upside: +9.28%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $14.42
Upside: +128.93%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $374.50
Upside: -19.36%
Alkermes
Oct 25, 2024
Maintains: Buy
Price Target: $32 → $30
Current: $31.34
Upside: -4.28%
Erasca
Oct 25, 2024
Maintains: Buy
Price Target: $3 → $3.5
Current: $1.86
Upside: +88.68%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $31.80
Upside: +60.38%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $151.51
Upside: +2.30%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $3.59
Upside: +11.58%
Revance Therapeutics
May 13, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $3.66
Upside: +118.88%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $16.00
Upside: +25.00%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $808.93
Upside: -10.62%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $25.19
Upside: +3.22%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $152.79
Upside: +0.14%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $176.64
Upside: -2.06%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.84
Upside: -
Nov 3, 2023
Maintains: Sell
Price Target: $4 → $1.25
Current: $0.80
Upside: +56.05%
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $59.64
Upside: +15.69%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $18.87
Upside: -31.11%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $41.09
Upside: -44.02%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $1.97
Upside: +2,438.07%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $39.73
Upside: +30.88%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $26.94
Upside: +122.76%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $13.11
Upside: +37.30%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $3.17
Upside: +436.28%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.15
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.44
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.07
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $12.45
Upside: -